[go: up one dir, main page]

RU2005138915A - Сульфонамид замещенные имидазохинолины - Google Patents

Сульфонамид замещенные имидазохинолины Download PDF

Info

Publication number
RU2005138915A
RU2005138915A RU2005138915/04A RU2005138915A RU2005138915A RU 2005138915 A RU2005138915 A RU 2005138915A RU 2005138915/04 A RU2005138915/04 A RU 2005138915/04A RU 2005138915 A RU2005138915 A RU 2005138915A RU 2005138915 A RU2005138915 A RU 2005138915A
Authority
RU
Russia
Prior art keywords
animal
substance
effective amount
salt according
imidazochinolins
Prior art date
Application number
RU2005138915/04A
Other languages
English (en)
Other versions
RU2374246C2 (ru
Inventor
Джордж В. ГРИЕСГРАБЕР (US)
Джордж В. ГРИЕСГРАБЕР
Original Assignee
3М Инновейтив Пропертиз Компани (US)
3М Инновейтив Пропертиз Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3М Инновейтив Пропертиз Компани (US), 3М Инновейтив Пропертиз Компани filed Critical 3М Инновейтив Пропертиз Компани (US)
Publication of RU2005138915A publication Critical patent/RU2005138915A/ru
Application granted granted Critical
Publication of RU2374246C2 publication Critical patent/RU2374246C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (5)

1. N-{2-[4-амино-2-(этоксиметил)-1H-имидазо-[4,5-c]-хинолин-1-ил]-1,1-диметилэтил}-метансульфонамид или фармацевтически приемлемая соль этого вещества.
2. Фармацевтическая композиция, содержащая терапевтически эффективное количество вещества или его соль по п.1 и фармацевтически приемлемый носитель.
3. Способ индукции биосинтеза цитокинов в организме животного, включающий введение эффективного количества вещества или его соли по п.1 в организм животного.
4. Способ лечения вирусного заболевания у животного, включающий введение эффективного количества вещества или его соли по п.1 в организм животного.
5. Способ лечения онкологического заболевания у животного, включающий введение эффективного количества вещества или его соли по п.1 в организм животного.
RU2005138915/04A 2003-06-27 2004-06-25 N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗО-[4,5-с]-ХИНОЛИН-1-ИЛ]-1,1-ДИМЕТИЛЭТИЛ}-МЕТАНСУЛЬФОНАМИД И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ RU2374246C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48320003P 2003-06-27 2003-06-27
US60/483,200 2003-06-27

Publications (2)

Publication Number Publication Date
RU2005138915A true RU2005138915A (ru) 2006-06-27
RU2374246C2 RU2374246C2 (ru) 2009-11-27

Family

ID=33563911

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005138915/04A RU2374246C2 (ru) 2003-06-27 2004-06-25 N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗО-[4,5-с]-ХИНОЛИН-1-ИЛ]-1,1-ДИМЕТИЛЭТИЛ}-МЕТАНСУЛЬФОНАМИД И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ

Country Status (16)

Country Link
EP (1) EP1638566A4 (ru)
JP (1) JP2007521280A (ru)
KR (1) KR20060035637A (ru)
CN (1) CN1812789B (ru)
AR (2) AR044923A1 (ru)
AU (1) AU2004253929A1 (ru)
BR (1) BRPI0411916A (ru)
CA (1) CA2529322A1 (ru)
IL (1) IL172427A0 (ru)
MX (1) MXPA06000144A (ru)
MY (1) MY157827A (ru)
NZ (1) NZ544330A (ru)
RU (1) RU2374246C2 (ru)
TW (2) TW200514784A (ru)
WO (2) WO2005003064A2 (ru)
ZA (1) ZA200600769B (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2005018556A2 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Hydroxylamine substituted imidazo-containing compounds
PH12006500401A1 (en) 2003-08-27 2005-03-10 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
EP1660026A4 (en) 2003-09-05 2008-07-16 3M Innovative Properties Co TREATMENT FOR CD5 + B CELL LYMPHOMA
CA2540598C (en) 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
EP1673087B1 (en) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
WO2005048945A2 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
EP1685129A4 (en) 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
WO2005055932A2 (en) * 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2005066169A2 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
AU2005228150A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
AU2005322898B2 (en) 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
ZA200706251B (en) * 2004-12-30 2008-11-26 Coley Pharm Group Inc Immune response modifier formulations and methods
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
WO2006086449A2 (en) 2005-02-09 2006-08-17 Coley Pharmaceutical Group, Inc. Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
EP1863814A1 (en) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006287270A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
WO2007035935A1 (en) * 2005-09-23 2007-03-29 Coley Pharmaceutical Group, Inc. METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF
US8951528B2 (en) 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
HRP20131139T1 (hr) * 2008-03-24 2014-01-03 4Sc Discovery Gmbh Novi supstituirani imidazokinolini
EP3222621B1 (en) 2010-08-17 2023-03-08 3M Innovative Properties Company Lipidated immune response modifier compound and its medical use
WO2012167088A1 (en) 2011-06-03 2012-12-06 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EP3366311B1 (en) 2011-06-03 2020-02-26 3M Innovative Properties Co. Hydrazino-1h-imidazoquinolin-4-amines and conjugates made therefrom
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
JP6873980B2 (ja) 2015-09-14 2021-05-19 ファイザー・インク ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
EP3484518B1 (en) 2016-07-07 2024-08-14 The Board of Trustees of the Leland Stanford Junior University Antibody adjuvant conjugates
SG11201908322WA (en) 2017-03-10 2019-10-30 Pfizer Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
PL3679025T3 (pl) 2017-09-06 2022-07-11 BioNTech SE Podstawione imidazochinoliny jako agoniści tlr7
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
CA3161668A1 (en) * 2019-12-20 2021-06-24 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
EP0894797A4 (en) * 1997-01-09 2001-08-16 Terumo Corp NEW AMID DERIVATIVES AND INTERMEDIATES ON YOUR SYNTHESIS
IL124914A (en) * 1997-06-26 2000-10-31 Akzo Nobel Nv Pharmaceutical compositions containing 6-aryl-2,3,5,6-tetrahydroimidazo¬2,1-a¾isoquinoline derivatives and some new such compounds
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
EP2145883A1 (en) * 1998-10-26 2010-01-20 The Research Foundation Of The State University Of New York Dibenzyl lipoic acid derivatives and their use in treatment of disease
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1719511B1 (en) * 2001-11-16 2008-12-10 3M Innovative Properties Company N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines

Also Published As

Publication number Publication date
IL172427A0 (en) 2006-04-10
AR044923A1 (es) 2005-10-12
WO2005003065A3 (en) 2005-03-10
CA2529322A1 (en) 2005-01-13
TW200511992A (en) 2005-04-01
AU2004253929A1 (en) 2005-01-13
WO2005003064A2 (en) 2005-01-13
NZ544330A (en) 2009-06-26
TW200514784A (en) 2005-05-01
MXPA06000144A (es) 2006-04-07
KR20060035637A (ko) 2006-04-26
JP2007521280A (ja) 2007-08-02
EP1638566A2 (en) 2006-03-29
AR044922A1 (es) 2005-10-12
WO2005003065A2 (en) 2005-01-13
EP1638566A4 (en) 2009-03-25
CN1812789A (zh) 2006-08-02
CN1812789B (zh) 2010-07-14
WO2005003064A3 (en) 2005-03-31
RU2374246C2 (ru) 2009-11-27
MY157827A (en) 2016-07-29
BRPI0411916A (pt) 2006-08-15
ZA200600769B (en) 2007-05-30

Similar Documents

Publication Publication Date Title
RU2005138915A (ru) Сульфонамид замещенные имидазохинолины
JP2007521280A5 (ru)
WO2007030775A3 (en) Amide and carbamate derivatives of n-{2-[4-amino-2- (ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
RU2314307C2 (ru) СОЕДИНЕНИЕ, ВКЛЮЧАЮЩЕЕ 2-МЕТИЛ-1-(2-МЕТИЛПРОПИЛ)-1Н-ИМИДАЗО[4,5-c][1,5]НАФТИРИДИН-4-АМИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБ СТИМУЛЯЦИИ БИОСИНТЕЗА ЦИТОКИНА В ОРГАНИЗМЕ ЖИВОТНЫХ
CY2009002I1 (el) Χρηση αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη του πονου
EP2860174A3 (en) Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation acivity
JP2005513021A5 (ru)
EE200200211A (et) Bitsüklilised aminohapped kui farmatseutilised toimeained
EE200200343A (et) Asaindooli sisaldav farmatseutiline kompositsioonraviotstarbeliseks kasutamiseks, asaindoolid ningnende kasutamine ravimite valmistamiseks, mis on ette nähtud proteiinikinaasi katalüütilise toime pärssimiseks
PT1183029E (pt) Preparado farmaceutico contendo contendo o principio activo diamorfina e sua utilizacao num processo para o tratamento da dependencia de opiaceos
CA2481848A1 (en) Active ingredient particles carrying clopidogrel or a salt thereof, their use and method of preparation
RU2003118797A (ru) Способ количественного определения состава многокомпонентных лекарственных препаратов жаропонижающего, аналгезирующего, противопростудного действия
MA27411A1 (fr) Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE60137069D1 (de) Arzneizusammensetzungen enthaltend modafinilverbindungen
AU8799001A (en) Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases
ITRM20030596A1 (it) Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
RU2006131553A (ru) Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap
DE60111459D1 (de) Zubereitungen zur transdermalen verabreichung hydrophiler substanzen
PL356127A1 (en) Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye
MA27110A1 (fr) Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1967208A4 (en) THERAPEUTIC AGENT FOR THE SKIN OR SKIN REPAIR PROMOTES THE MEDIUM WITH GHRELIN, A DERIVATIVES THEREOF OR A SUBSTANCE THAT CAN APPLY ON GHS-R1a; AS AN ACTIVE SUBSTANCE
EA200500687A1 (ru) Применение дистронциевой соли 2-[n,n-ди(карбоксиметил)амино]-3-циано-4-карбоксиметилтиофен-5-карбоновой кислоты при получении лекарственных средств, предназначенных для лечения гастродуоденальной боли
IL152751A0 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
ITUD20030196A1 (it) Procedimento per la preparazione di dosaggi farmaceutici contenenti molteplici principi attivi.
EA200501765A2 (ru) Средство для лечения болезней суставов

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110626